Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)

被引：0
|
作者：
Oh, Do-Youn
Lugowska, Iwona A.
Stroyakovskiy, Daniil
Jung, Kyung Hae
Dumas, Olivier
Penkov, Konstantin
Dechaphunkul, Arunee
Oaknin, Ana
Kim, Seung Tae
Starling, Naureen
Chewaskulyong, Busyamas
Charonpongsuntorn, Chanchai
Doroshow, Deborah Blythe
Hsiao, Sheng-Yen
Hung, Yi-Ping
Jung, Lindsey
Kuptsova-Clarkson, Nataliya
Michelini, Flavia
Puvvada, Soham D.
Meric-Bernstam, Funda
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[2] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Dept, Warsaw, Poland
[3] Moscow City Oncol Hosp 62, Moscow, Russia
[4] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Hotel Dieu Quebec, Quebec City, PQ, Canada
[6] Clin Hosp RZHD Med, St Petersburg, Russia
[7] Prince Songkla Univ, Dept Med, Med Oncol Unit, Fac Med, Hat Yai, Thailand
[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol, Gynaecol Canc Programme, Barcelona, Spain
[9] Samsung Med Ctr, Seoul, South Korea
[10] Royal Marsden NHS Fdn Trust, Gastrointestinal Unit, London, England
[11] Inst Canc Res, London, England
[12] Chiang Mai Univ, Chiang Mai, Thailand
[13] Srinakharinwirot Univ, Dept Internal Med, Med Oncol Unit, Fac Med, Nakhon Nayok, Thailand
[14] Icahn Sch Med Mt Sinai, New York, NY USA
[15] Chi Mei Med Ctr, Div Hematol Oncol, Dept Internal Med, Tainan, Taiwan
[16] Taipei Vet Gen Hosp, Taipei, Taiwan
[17] AstraZeneca, Gaithersburg, MD USA
[18] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[19] AstraZeneca, Translat Med, Oncol R&D, Waltham, MA USA
[20] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4090
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
    Hamilton, E. P.
    Shapiro, C. L.
    Boni, V.
    Jimenez, M. Martin
    Del Conte, G.
    Cortes, J.
    Agrawal, L.
    Arkenau, H-T.
    Tan, A. R.
    Debruyne, P. R.
    Minchom, A. R.
    Rutten, A.
    Valdes-Albini, F.
    Yu, E.
    Suto, F.
    Cheng, F-C.
    Augustine, B.
    Cheng, B.
    Barrios, D.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S196 - S196
  • [42] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [44] Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINYeLung02 (DL-02)
    Goto, Y.
    Goto, K.
    Kubo, T.
    Ninomiya, K.
    Kim, S-W.
    Ahn, M-J.
    Nakagawa, K.
    Hayashi, H.
    Shimizu, J.
    Kim, D-W.
    Yang, J. C-H.
    Kuo, C-H. S.
    Lee, K. H.
    Yang, T-Y.
    Pereira, K. M. C.
    Taguchi, A.
    Ali, A.
    Cheng, F-C.
    Yonemochi, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1666 - S1667
  • [45] Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer
    Tarantino, Paolo
    Lee, Do
    Foldi, Julia
    Soulos, Pamela R.
    Gross, Cary Philip
    Grinda, Thomas
    Winer, Eric P.
    Lin, Nancy U.
    Krop, Ian E.
    Tolaney, Sara M.
    Lustberg, Maryam B.
    Sammons, Sarah L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
    Hamilton, Erika
    Shapiro, Charles L.
    Petrylak, Daniel
    Boni, Valentina
    Martin, Miguel
    Del Conte, Gianluca
    Cortes, Javier
    Agarwal, Laila
    Arkenau, Hendrik-Tobias
    Tan, Antoinette R.
    Debruyne, Philip
    Minchom, Anna
    Rutten, Annemie
    Valdes-Albini, Frances
    Yu, Evan Y.
    Augustine, Bincy
    D'Amelio, Anthony, Jr.
    Barrios, Daniel
    Hurvitz, Sara A.
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours
    Takahashi, M.
    Bang, Y-J.
    Karayama, M.
    Watanabe, J.
    Minami, H.
    Yamamoto, N.
    Kinoshita, I.
    Lin, C. C.
    Im, Y-H.
    Fujiki, T.
    Achiwa, I.
    Kamiyama, E.
    Okuda, Y.
    Lee, C.
    Takahashi, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S68 - S69
  • [48] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [49] Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
    Curigliano, G.
    Dunton, K.
    Rosenlund, M.
    Janek, M.
    Cathcart, J.
    Liu, Y.
    Fasching, P. A.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S196 - S197
  • [50] Exposureefficacy and safety analysis of trastuzumab deruxtecan (T-DXd) in patients with advanced/metastatic HER2+breast cancer (BC): Analyses from Phase 3 Studies DESTINYBreast02 (DB-02) and DESTINYBreast03 (DB-03)
    Li, Claire
    Wada, Russ
    Li, Hanbin
    Kastrissios, Helen
    Abutarif, Malaz
    Garimella, Tushar
    Khatri, Amit
    CANCER RESEARCH, 2024, 84 (09)
12345